

1 **[*Online data supplement*]**

2 **Airway epithelial phosphoinositide 3-kinase delta contributes to**  
3 **the modulation of fungi-induced innate immune response**

4

5 **Jae Seok Jeong, Kyung Bae Lee, So Ri Kim, Dong Im Kim, Hae Jin Park, Hern-Ku Lee,**  
6 **Hyung Jin Kim, Seong Ho Cho, Narasaiah Kolliputi, Soon Ha Kim, Yong Chul Lee\***

7

8 **Table of Contents**

9 **Supplementary Methods (pages 2-13)**

10 **Supplementary References (pages 14)**

11 **Supplementary Figure Legends (pages 15-24)**

## 1 SUPPLEMENTARY METHODS

### 2 **Animals and experimental protocol**

3 Female C57BL/6 mice, 8 to 10 weeks of age and free of murine specific pathogens, were  
4 obtained from the Orient Bio Inc. (Seoungnam, Korea), housed throughout the experiments in  
5 a laminar flow cabinet and maintained on standard laboratory chow *ad libitum*. In addition,  
6 p110 $\delta$  knockout (KO) mice genetically deficient for catalytic subunit of phosphoinositide 3-  
7 kinase (PI3K)- $\delta$  (p110 $\delta$ ) were purchased from the Jackson Laboratory (Sacramento, CA,  
8 USA). PI3K- $\delta$  KO mice were generated using strain 129S5/SvEv-derived embryonic stem  
9 cells by Gene Trap method through retroviral insertion that disrupt the gene between coding  
10 exons 3 and 4 of mouse *Pik3cd* gene, the ortholog of human PIK3CD which encodes p110 $\delta$ .  
11 Backcross to C57BL/6 was performed throughout the study. All animal experiments were  
12 approved by the Institutional Animal Care and Use Committee of the Chonbuk National  
13 University (CBU 2014-00030) and were performed in accordance with the ARRIVE (Animal  
14 Research: Reporting of In Vivo Experiments) guidelines. For the generation of an *Aspergillus*  
15 *fumigatus* (*Af*)-induced allergic lung inflammation model, all mice received mixture of a total  
16 of 10  $\mu$ g of *Af* crude antigen extract (Greer Laboratories, Lenoir, NC, USA), in which the  
17 cellular fungal material was inactivated and lyophilized, and 0.2 ml of incomplete Freund's  
18 adjuvant (Sigma-Aldrich, St. Louis, MO, USA) dissolved in normal saline. One-half of this  
19 preparation was then deposited in the peritoneal cavity, and the remainder was delivered  
20 subcutaneously. Two weeks later, mice received a total of 20  $\mu$ g of *Af* antigens dissolved in  
21 normal saline via the intranasal route. Four days after the intranasal challenge, mice received  
22 20  $\mu$ g of *Af* antigen dissolved in normal saline via the intratracheal route. In the *Alternaria*  
23 *alternata* (*Aa*)-induced allergic lung inflammation model, all mice were treated with the  
24 mixture of a total of 25  $\mu$ g of *Aa* crude antigen extract dissolved in normal saline via

1 intranasal route on days 0, 3, 6, and 9, as previously described elsewhere.<sup>1</sup>

2

### 3 **Administration of drugs**

4 A selective inhibitor of catalytic subunit of PI3K- $\delta$ , IC87114 (0.1 or 1.0 mg/kg body  
5 weight/day, Calbiochem, San Diego, CA, USA) was administered one time by intratracheal  
6 instillation to each animal 24 hours after the last challenge with *Af* or *Aa*. Dexamethasone (1  
7 mg/kg body weight/day, Sigma-Aldrich) was administered two times by means of oral gavage  
8 to each animal, once 24 hours before and again at two hours before the last challenge with *Af*  
9 or *Aa*. A mitochondrial reactive oxygen species (mtROS) scavenger, NecroX-5 (30 mg/kg  
10 body weight/day, Enzo Life Sciences, Farmingdale, NY, USA) was administered two times  
11 by intraperitoneal injection to each animal 24 hours before and after the last challenge with  
12 *Af*. MCC 950 (50 mg/kg body weight/day, Cayman Chemical Co., Ann Arbor, MI, USA), a  
13 selective inhibitor of NLRP3 inflammasome,<sup>2</sup> was administered one time by intraperitoneal  
14 injection to each animal one hour before the last challenge with *Af* or *Aa*. Anti-IL-1 $\beta$  antibody  
15 (Ab) or isotype control Ab (100  $\mu$ g/kg body weight/day, eBioscience, San Diego, CA, USA)  
16 was administered intravenously two times to each animal at 24 hours before and after the last  
17 challenge with *Af*.

18

### 19 **Bronchoalveolar lavage (BAL)**

20 BAL was performed at 72 hours after the last challenge with *Af* or *Aa*. At the time of lavage,  
21 the mice (5-7 mice in each group) were killed by means of cervical dislocation. The chest  
22 cavity was exposed to allow for expansion, after which the trachea was carefully intubated  
23 and the catheter was secured with ligatures. Prewarmed 0.9% NaCl solution was slowly  
24 instilled into the lung and withdrawn. The collected solutions were pooled and kept at 4 °C.

1 A part of each pool was then centrifuged, and the supernatants were kept at  $-70^{\circ}\text{C}$  until use.  
2 Total cell numbers were counted with a hemocytometer. Smears of BAL cells were prepared  
3 by cytopsin (Thermo Fisher Scientific Inc., Waltham, MA, USA) and stained with Diff-Quik  
4 solution (Dade Diagnostics of Puerto Rico Inc., Aguada, Puerto Rico) in order to examine  
5 cell differentials. Level of IL-1 $\beta$  protein in BAL fluids was measured using IL-1 $\beta$  enzyme-  
6 linked immunosorbent assay (ELISA) kit (eBioscience), according to the manufacturer's  
7 protocol.

8

### 9 **Cell viability assay**

10 To assess the potential toxic effect of the IC87114, viability assay of BAL cells was  
11 performed after intratracheal administration of the drug in both normal and *Af*-exposed mice,  
12 using the automated NucleoCounter NC-100 (Chemometec, Denmark) according to the  
13 manufacturer's protocol.

14

### 15 **Measurement of PI3K enzyme activity in lung tissue**

16 Whole lung tissues were homogenized in the presence of protease inhibitors to obtain  
17 extracts of lung proteins. Protein concentrations were determined using the Bradford reagent  
18 (Bio-Rad Laboratories Inc., Hercules, CA, USA). The amount of PIP<sub>3</sub> produced was  
19 quantified by the PIP<sub>3</sub> competition enzyme immunoassay according to the manufacturer's  
20 protocol (Echelon, Santa Clara, CA, USA). The enzyme activity was expressed as pmol PIP<sub>3</sub>  
21 produced in 1 ml of lung tissue extract containing equal amounts of total protein.

22

### 23 **Serum total IgE and *Af*-specific IgE**

1 For the *Af*-specific IgE assay, 96-well immunosorbent plates were coated with *Af* antigen (10  
2  $\mu\text{g/ml}$ , Greer Laboratories) in carbonate-bicarbonate buffer (Sigma-Aldrich). After blocking  
3 the plates with 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS), serially  
4 diluted mouse serum was added. The plates were incubated for two hours at 37 °C.  
5 Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgE Ab (Bethyl Laboratories,  
6 Montgomery, TX, USA) was used to detect *Af*-bound IgE. The plates were developed with  
7 tetramethylbenzidine substrate (Bethyl Laboratories), and the reaction was stopped with  
8  $\text{H}_2\text{SO}_4$ , and the absorbance was determined at 450 nm. Total serum IgE was measured using a  
9 mouse Total IgE ELISA Kit (MD Bioproducts, St. Paul, MN, USA) according to the  
10 manufacturer's protocol.

11

## 12 **Isolation and primary culture of murine tracheal epithelial cells (EpCs) and IC87114** 13 **treatment**

14 Murine tracheal EpCs were isolated under sterile conditions as described previously.<sup>3</sup>  
15 Briefly, the EpCs were seeded onto 60-mm collagen-coated dishes for submerged culture.  
16 The growth medium, DMEM (Thermo Fisher Scientific Inc.) containing 10% fetal bovine  
17 serum (FBS), penicillin, streptomycin, and amphotericin B, was supplemented with insulin,  
18 transferrin, hydrocortisone, phosphoethanolamine, cholera toxin, ethanolamine, bovine  
19 pituitary extract, and BSA. The cells were maintained in a humidified 5%  $\text{CO}_2$  incubator at  
20 37 °C until they adhered. Cells were treated with IC87114 (10  $\mu\text{mol/l}$ ) for two hours, and  
21 then stimulated by *Af* antigen (5  $\mu\text{g/ml}$ ) for additional 12 hours.

22

## 23 **Normal human bronchial epithelial (NHBE) cells culture and treatment**

1 NHBE cells were purchased from Lonza (Walkersville, MD, USA). The cells were cultured  
2 in bronchial epithelial basal medium (BEBM, Lonza) supplemented with 10% (v/v) FBS  
3 (Lonza), bovine pituitary extract, gentamicin, amphotericin B, hydrocortisone, epidermal  
4 growth factor, epinephrine, insulin, triiodothyronine, transferrin, and retinoic acid, which  
5 were maintained in a humidified incubator of 5% CO<sub>2</sub> atmosphere at 37 °C. Cells were  
6 seeded in culture dishes and grown until 70% confluence. Cells were treated with IC87114  
7 (10 μmol/l) for two hours, and then stimulated by *Af* antigen (5 μg/ml) for additional 12  
8 hours.

9

#### 10 **PI3K-δ specific siRNA transfection in primary cultured tracheal EpCs and NHBE cells**

11 To analyze the silencing effect of siRNA, RNA was extracted from cells using TRIzol  
12 (Thermo Fisher Scientific Inc.) as previously described,<sup>4</sup> and quantitative real-time reverse  
13 transcription polymerase chain reaction (RT-PCR) analysis was performed using the  
14 LightCycler<sup>®</sup> FastStart DNA Master SYBR Green I (Roche Diagnostics, Mannheim,  
15 Germany). Real-time RT-PCR data were analyzed by the comparative cycle threshold method  
16 with the LightCycler<sup>®</sup> Software version 4.1 and normalized to internal controls (β-actin). The  
17 primers used were: PI3K-δ sense: 5'-CACAGGTCTCATCGAGGTGGTC-3', antisense: 5'-  
18 TGGACTTGAGCCAGTTGAGCA-3' and β-actin sense: 5'-CAGATCATGTTTGAGACCT  
19 TC-3', antisense: 5'-ACTTCATGATGGAATTGAATG-3'. As for siRNA knockdown of  
20 NHBE cells, the cells were transfected using ON-TARGETplus siRNA against PI3K-δ  
21 (PIK3CD, catalog no. L-006775-00) (Thermo Fisher Scientific Inc., Waltham, MA, USA) or  
22 ON-TARGETplus Non-targeting siRNA at a final concentration of 10 nM. The transfection  
23 agent was DharmaFECT 4 from Thermo Scientific Inc., and Opti-MEM I reduced serum  
24 medium (Invitrogen, Carlsbad, CA, USA) was used to dilute siRNA and transfection agent,

1 according to the manufacturer's protocol. siRNAs (10 nM) were transfected 24 hours before  
2 the stimulation of NHBE cells with *Af*.

3

#### 4 **Immunofluorescence staining for NLRP3, Caspase-1, and ASC and cytoplasmic** 5 **localization of mtROS**

6 Paraffin-embedded lung tissue sections were deparaffinized and hydrated. The sections and  
7 *Af*-stimulated primary cultured tracheal EpCs were fixed with ice cold methanol and  
8 permeabilized in PBS containing 0.25% Triton X-100 for 10 minutes at room temperature  
9 and washed three times with PBS. Subsequently, after antigen retrieval for 15 minutes at 37  
10 °C in proteinase K (Dako, Glostrup, Denmark), nonspecific bindings were blocked with 1%  
11 BSA (Sigma-Aldrich) in PBS containing 0.05% Tween 20 for one hour. Specimens were then  
12 incubated in a humidified chamber for two hours at room temperature with an Ab to NLRP3  
13 (Adipogen International, San Diego, CA, USA), Ab to Caspase-1 (Santa Cruz Biotechnology,  
14 Dallas, TX, USA), and Ab to ASC (Santa Cruz Biotechnology). For the detection of primary  
15 Ab, Alexa Fluor 546 (red) labeled goat anti-mouse IgG (Thermo Fisher Scientific Inc.) for  
16 NLRP3 and Alexa Fluor 488 (green) labeled goat anti-rabbit IgG (Thermo Fisher Scientific  
17 Inc.) for caspase-1 or ASC, in 1% BSA were loaded for one hour at room temperature in  
18 dark, respectively. After the specimens were washed, nuclei were stained using 4',6-  
19 diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific Inc.). Stained specimens were  
20 mounted on slides using fluorescent mounting medium (Golden Bridge International, Inc.,  
21 Mukilteo, WA, USA), and then visualized using a confocal laser scanning microscope (Zeiss  
22 LSM 510 Meta, Carl Zeiss, Jena, Germany) installed in the Center for University Research  
23 Facility (CURF) at Chonbuk National University. To demonstrate the immunofluorescence  
24 intensity of mtROS in BAL cells, collected cells were stained with MitoTracker Red CM-

1 H<sub>2</sub>Xros (Thermo Fisher Scientific Inc.) and DAPI, then analyzed using a confocal laser  
2 scanning microscope.

3

#### 4 **Immunohistochemistry (IHC)**

5 Human lung tissue sections came from regional bank of biospecimen in Chonbuk National  
6 University Hospital supported by the Korea Bank Project, Ministry for Health and Welfare,  
7 Republic of Korea. All samples were deidentified, and all experimental protocols regarding  
8 human tissues were approved by the Institutional Review Board of the Biomedical Research  
9 Institute of Chonbuk National University Hospital (IRB file No. 2013-11-007-001). For IHC  
10 of NLRP3, the deparaffinized 4- $\mu$ m sections were incubated sequentially according to the  
11 instruction using the R. T. U. Vectastain Universal Quick kit from Vector Laboratories Inc.  
12 (Burlingame, CA, USA). Briefly, the slides were incubated in 3% H<sub>2</sub>O<sub>2</sub> for 20 minutes and in  
13 pepsin for 10 minutes at 37 °C. Then, the slides were incubated in normal horse serum for 30  
14 minutes at room temperature, probed with Ab to NLRP3 (Santa Cruz Biotechnology) for two  
15 hours at room temperature, and then incubated with prediluted biotinylated pan-specific IgG  
16 for 30 minutes. To visualize the Ab reactivity, the slides were incubated in  
17 streptavidin/peroxidase complex reagent for 15 minutes and then in 3-amino-9-ethylcarbazole  
18 substrate kit for 5 minutes. Controls consisted of sections of normal human lung tissues were  
19 incubated without the primary Ab. After immunostaining, the slides were  
20 photomicrographed.

21 Clinical information regarding lung tissues of healthy controls (3 persons), patients with  
22 idiopathic pulmonary fibrosis (IPF) (4 persons) or patients with allergic bronchopulmonary  
23 aspergillosis (ABPA) (6 patients) was evaluated through assessing previous medical records  
24 from the Chonbuk National University Hospital. Patients who met at least four of the classic



1 diagnostic criteria for ABPA were considered to have ABPA.<sup>5</sup> Briefly, 1) presence of  
2 bronchial asthma, 2) immediate cutaneous hyperreactivity on *Aspergillus* skin test (type I  
3 hypersensitivity reaction), 3) elevated serum IgE (>417 IU/ml), 4) elevated serum *Af*-specific  
4 IgE and/or IgG levels (>0.35 kUA/l), 5) precipitating Abs (IgG) in serum against *Af*, 6)  
5 eosinophilia (>1000 cells/ml), 7) central bronchiectasis, and 8) transient or fixed pulmonary  
6 opacities on images. The *Aspergillus* skin test was performed using *Af* antigen (Bencard,  
7 Bradford, UK). The test was interpreted after 15 to 20 minutes. At least 3-mm diameter wheal  
8 with equivalent erythema more than diluent control done at the same time was considered as  
9 type I cutaneous hypersensitivity reaction. Levels of serum total IgE and *Af*-specific IgG were  
10 measured by commercially available kits using the fluorescent enzyme immunoassay. *Af*-  
11 specific IgE and precipitins for *Af* were not measured due to the limitation of our facilities.

12

### 13 **Western blot analysis**

14 Lung tissues or *Af*-stimulated primary cultured tracheal EpCs were homogenized in the  
15 presence of protease inhibitor cocktail (Sigma-Aldrich), and protein concentrations were  
16 determined using Bradford reagent (Bio-Rad Laboratories). For Western blot analysis,  
17 samples were loaded onto a SDS-PAGE gel. After electrophoresis at 120 V for 90 minutes,  
18 proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad  
19 Laboratories) at 250 mA for 90 minutes by a wet transfer method. Nonspecific sites were  
20 blocked with 5% non-fat dry milk in Tris-buffered saline Tween 20 (TBST; 25 mmol/l Tris  
21 pH 7.5, 150 mmol/l NaCl, 0.1% Tween 20) for one hour, and the blots were then incubated  
22 overnight at 4 °C with an Ab to IL-4 (AbD Serotec, Kidlington, UK), Ab to IL-5 (Santa Cruz  
23 Biotechnology), Ab to IL-13 (R&D Systems, Minneapolis, MN, USA), Ab to NLRP3  
24 (Adipogen international), Ab to Caspase-1 (Santa Cruz Bitotechnology), Ab to IL-1 $\beta$

1 (Thermo Fisher Scientific Inc.), Ab to p-AKT (R&D Systems), Ab to AKT (Cell Signaling  
2 Technologies, Danvers, MA, USA), and Ab to actin (Sigma-Aldrich). Anti-rabbit or anti-  
3 mouse HRP-conjugated IgG (Cell Signaling Technologies) was used to detect binding of  
4 Abs. The binding of the specific Ab was visualized by exposing to photographic film after  
5 treating with enhanced chemiluminescence system reagents (Promega Co., Madison, WI,  
6 USA). The film was scanned (ImageScanner III, GE Healthcare, Little Chalfont,  
7 Buckinghamshire, UK) and quantified using a quantification software (Gel Doc XR, Bio-Rad  
8 Laboratories). For the quantification of specific bands, the square with same size was drawn  
9 around each band to measure the density and then the value was adjusted by the density of  
10 the background near that band. The results of densitometric analysis were expressed as a  
11 relative ratio of the target protein to reference protein. The relative ratio of the target protein  
12 of control group is arbitrarily presented as 1.

13

#### 14 **Immunoprecipitation (IP)**

15 Lung tissue homogenates were obtained in the presence of protease inhibitor cocktail (Sigma-  
16 Aldrich) and protein concentrations were determined using Bradford reagent (Bio-Rad  
17 Laboratories). Co-IP of NLRP3 and interacting proteins was performed using Dynabeads  
18 protein G (ThermoFisher Scientific) according to the manufacturer's instructions. Briefly,  
19 anti-mouse NLRP3 Ab (Adipogen international) diluted in PBS with 0.02% Tween 20 was  
20 incubated with Dynabeads protein G for 10 minutes at room temperature and beads-Ab  
21 complex was isolated. Then, lung tissue homogenates were added and incubated for 10  
22 minutes at room temperature to produce antigen-Ab-beads complex. Finally, protein  
23 components containing NLRP3 were eluted with Elution buffer (50 mM glycine pH 2.8) and  
24 were analyzed by Western blotting.

1

**2 Trichloroacetic acid (TCA)-mediated protein precipitation of BAL fluids**

3 TCA-mediated protein precipitation of BAL fluids was performed according to the method  
4 described elsewhere with some modifications.<sup>6</sup> In this study, saline of 1 ml was instilled for  
5 all lavages and 700  $\mu$ l of BAL fluids were obtained from each mouse. Thereafter, we  
6 performed TCA-mediated protein precipitation of BAL fluids and determined the levels of  
7 secreted mature IL-1 $\beta$  in BAL fluids. In short, BAL fluids were centrifuged at 3000  $\times$  *g* for 2  
8 minutes to remove cell debris. 100% TCA solution (Sigma-Aldrich) was added to the  
9 supernatants to a final concentration of 20% TCA and incubated for 10 minutes at 4 °C.  
10 Then, the samples were centrifuged at 16000  $\times$  *g* for 5 minutes and the pellets were washed  
11 with cold acetone. After centrifugation at 16000  $\times$  *g* for two minutes, the pellets were  
12 resuspended in protein lysis buffer in the presence of protease inhibitor and analyzed by  
13 Western blotting.

14

**15 ASC oligomerization assay**

16 ASC oligomerization assay was performed according to the method described elsewhere  
17 with some modifications.<sup>7</sup> Briefly, primary cultured tracheal EpCs were harvested two hours  
18 after treatment with IC87114, and cytosolic fractions were isolated through resuspending  
19 cells in 0.3 ml buffer containing 20 mM HEPES (pH 7.5), 150 mM KCL, 1.5mM MgCl<sub>2</sub>, 1m  
20 M EGTA, 1mM EDTA, 320 mM sucrose, and protease inhibitor mixture. Cell lysates were  
21 centrifuged at 520  $\times$  *g* for 10 minutes. Supernatants were diluted with equal volume of 3-[(3-  
22 Cholamidopropyl)-dimethylammonio]-1-propane sulfonate (CHAPS) buffer [20 mM HEPES  
23 (pH 7.5), 5 mM MgCl<sub>2</sub>, 0.5 mM EGTA, 0.1% CHAPS]. After the centrifugation at 4000  $\times$  *g*  
24 for 10 minutes, pelletes containing ASC oligomers were isolated. And, cross-linking of ASC

1 oligomers was performed through resuspending the pellets in CHAPS buffer containing 2  
2 mM disuccinimidyl suberate (DSS) cross-linker. The cross-linked pellets were then collected  
3 by centrifugation at  $4000 \times g$  for 10 minutes and ASC oligomerization was analyzed by  
4 immunoblotting with Ab to ASC (Santa Cruz Biotechnology).

5

## 6 **Histology**

7 At 72 hours after the last *Af* or *Aa* challenge, mice were euthanized for histological  
8 assessment. Lung and trachea of mice were removed from the mice. For fixation, 10%  
9 (volume/volume) neutral buffered formalin was used. Specimens were dehydrated and  
10 embedded in paraffin. For histological examination, 4- $\mu$ m sections of fixed embedded tissues  
11 were cut on a Leica model 2165 rotary microtome (Leica Microsystem Nussloch GmbH,  
12 Wetzlar, Germany), placed on glass slides, deparaffinized, and stained sequentially with  
13 H&E (Richard-Allan Scientific, Kalamazoo, MI, USA). Stained tissue sections on slides were  
14 analyzed under identical light microscope (Axio Imager M1, Carl Zeiss) conditions,  
15 including magnification ( $\times 20$ ), gain, camera position, and background illumination.

16

## 17 **Determination of airway responsiveness to methacholine**

18 Anesthesia was performed through intraperitoneal injection of 45 mg/kg body weight of  
19 sodium pentobarbital. The trachea was then exposed through midcervical incision,  
20 tracheostomized, and an 18-gauge metal needle was inserted. Mice were connected to a  
21 computer-controlled small animal ventilator (flexiVent, SCIREQ, Montreal, Canada). The  
22 mouse was quasi-sinusoidally ventilated with nominal tidal volume of 10 ml/kg body weight  
23 at a frequency of 150 breaths/minutes and a positive end-expiratory pressure of 2 cm H<sub>2</sub>O to  
24 achieve a mean lung volume close to that during spontaneous breathing. This was achieved

1 by connecting the expiratory port of the ventilator to water column. Methacholine aerosol  
2 was generated with an in-line nebulizer and administered directly through the ventilator. To  
3 determine the differences in airway response to methacholine, each mouse was challenged  
4 with methacholine aerosol in increasing concentrations (5.0 to 50 mg/ml in saline). After  
5 each methacholine challenge, the data of calculated  $R_{rs}$  were continuously collected.  
6 Maximum values of  $R_{rs}$  were selected to express changes in airway function, which was  
7 represented as a percentage change from the baseline after saline aerosol.

8

### 9 **Statistics**

10 We used SPSS statistical software (version 18.0, SPSS, Chicago, IL, USA). Data are  
11 expressed as mean  $\pm$  SEM. Statistical comparisons were performed using one-way ANOVA  
12 followed by the Scheffe's test. Significant differences between two groups (analyses between  
13 control and *Af*-exposed groups and analyses between *Af*-exposed wild type and *Af*-exposed  
14 *p110 $\delta$*  KO mice) were determined using unpaired t-test. A value of  $P < 0.05$  was considered  
15 statistically significant.

1 **SUPPLEMENTARY REFERENCES**

- 2 **1.** Oczypok EA, Milutinovic PS, Alcorn JF, *et al.* Pulmonary receptor for advanced glycation  
3 end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2  
4 innate lymphoid cells. *J Allergy Clin Immunol* 2015;136:747-56.
- 5 **2.** Coll RC, Robertson AA, Chae JJ, *et al.* A small-molecule inhibitor of the NLRP3  
6 inflammasome for the treatment of inflammatory diseases. *Nat Med* 2015;21:248-55.
- 7 **3.** Kwak YG, Song CH, Yi HK, *et al.* Involvement of PTEN in airway hyperresponsiveness  
8 and inflammation in bronchial asthma. *J Clin Invest* 2003;111:1083-92.
- 9 **4.** Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium  
10 thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987;162:156-9.
- 11 **5.** Patterson R, Greenberger PA, Halwig JM, *et al.* Allergic bronchopulmonary aspergillosis.  
12 Natural history and classification of early disease by serologic and roentgenographic studies.  
13 *Arch Intern Med* 1986;146:916-8.
- 14 **6.** De Francesco EM, Lappano R, Santolla MF, *et al.* HIF-1 $\alpha$ /GPER signaling mediates the  
15 expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs).  
16 *Breast Cancer Res* 2013;15:R64.
- 17 **7.** Chuang SY, Yang CH, Chou CC, *et al.* TLR-induced PAI-2 expression suppresses IL-1 $\beta$   
18 processing via increasing autophagy and NLRP3 degradation. *Proc Natl Acad Sci USA*  
19 2013;110:16079-84.

## 1 SUPPLEMENTARY FIGURE LEGENDS

2 **Supplementary Figure 1.** NLRP3 inflammasome is implicated in *Aspergillus fumigatus*  
3 (*Af*)-induced allergic lung inflammation. (A-C) Quantifications of the immunofluorescence  
4 intensities for NLRP3 (A) and caspase-1 (Casp-1; B) and their cytoplasmic co-localization (C)  
5 in bronchoalveolar lavage (BAL) cells from saline-exposed (Control) or *Aspergillus*  
6 *fumigatus*-exposed (*Af*) mice. (D-F) Quantifications of the immunofluorescence intensities  
7 for ASC (D) and NLRP3 (E) and their cytoplasmic co-localization (F) in BAL cells from  
8 Control or *Af* mice. (G-I) Quantifications of the immunofluorescence intensities for NLRP3  
9 (G) and Casp-1 (H) and their co-localization (I) in lung tissues of Control or *Af* mice. Bars  
10 represent mean  $\pm$  SEM from six mice per group. <sup>#</sup> $P < 0.05$  versus control. (J) Quantifications  
11 of the immunofluorescence intensities for NLRP3 in lung tissues from healthy controls,  
12 patients with idiopathic pulmonary fibrosis (IPF; disease controls), and patients with allergic  
13 bronchopulmonary aspergillosis (ABPA), respectively. (K) Quantifications of the  
14 immunohistochemical staining score for NLRP3 in lung tissues from healthy controls,  
15 patients with IPF, and patients with ABPA, respectively. Bars represent mean  $\pm$  SEM from 3  
16 persons in healthy control group, 4 persons in IPF patient group, and 6 persons in ABPA  
17 patient group. <sup>#</sup> $P < 0.05$  versus healthy control group; <sup>\*</sup> $P < 0.05$  versus IPF patient group.

18

19 **Supplementary Figure 2.** *Aspergillus fumigatus* (*Af*) stimulation leads to NLRP3  
20 inflammasome assembly in tracheal epithelial cells (EpCs). (A) Representative confocal  
21 images of tracheal EpCs show the localization of NLRP3 (red) and caspase-1 (Casp-1, green)  
22 in normal (Control) or *Af*-stimulated (*Af*) cells under low power field of view. Bars indicate  
23 50  $\mu$ m. (B-D) Quantifications of the immunofluorescence intensities for NLRP3 (B) and  
24 Casp-1 (C) and their co-localization (D) in Control or *Af* cells. (E) Representative confocal

1 images of tracheal EpCs show the localization of ASC (green) and NLRP3 (red) in Control or  
2 *Af* cells under low power field of view. Bars indicate 50  $\mu\text{m}$ . (F-H) Quantifications of the  
3 immunofluorescence intensities for ASC (F) and NLRP3 (G) and their co-localization (H) in  
4 Control or *Af* cells. Bars represent mean  $\pm$  SEM from six independent experiments.  $^{\#}P < 0.05$   
5 versus control.

6

7 **Supplementary Figure 3.** Phosphoinositide 3-kinase (PI3K)- $\delta$  inhibition improves  
8 *Aspergillus fumigatus* (*Af*)-induced allergic lung inflammation. (A) Schematic diagram of the  
9 experimental protocol involving IC87114. i.p: intraperitoneal, s.c: subcutaneous, i.n:  
10 intranasal, i.t: intratracheal. (B and C) Representative immunoblots of phosphorylated (p)-  
11 AKT and total (t)-AKT (B) and densitometric analyses of p-AKT (C) in lung tissues from  
12 saline-sensitized/challenged mice administered drug vehicle (SAL+VEH), *Af*-  
13 sensitized/challenged mice administered drug vehicle (*Af*+VEH), *Af*-sensitized/challenged  
14 mice administered 0.1 mg/kg IC87114 (*Af*+IC 0.1) or *Af*-sensitized/challenged mice  
15 administered 1.0 mg/kg IC87114 (*Af*+IC 1.0). Bars represent mean  $\pm$  SEM from 6 mice per  
16 group. (D) Enzyme immunoassays of PIP3 in the lung. Bars represent mean  $\pm$  SEM from 6  
17 mice per group. (E) Levels of total IgE and *Af*-specific IgE in the serum. Bars represent mean  
18  $\pm$  SEM from 6 mice per group. ND: not detected. (F-I) Representative H&E stained sections  
19 of the lung from SAL+VEH (F), *Af*+VEH (G), *Af*+IC 0.1 (H) or *Af*+IC 1.0 (I). Bars indicate  
20 scale of 50  $\mu\text{m}$ . (J) Airway responsiveness assessed by invasive ( $R_{rs}$ ) measurements. Bars  
21 represent mean  $\pm$  SEM from 6 mice per group. (K) Cellular changes in bronchoalveolar  
22 lavage fluids. Bars represent mean  $\pm$  SEM from 6 mice per group. (L-Q) Representative  
23 immunoblots of IL-4 (L), IL-5 (N), and IL-13 (P) in lung tissues and densitometric analyses  
24 of IL-4 (M), IL-5 (O), and IL-13 (Q). Bars represent mean  $\pm$  SEM from 6 mice per group.  $^{\#}P$



1 < 0.05 versus SAL+VEH; \*  $P < 0.05$  versus *Af*+VEH.

2

3 **Supplementary Figure 4.** Quantifications for the protein expressions of NLRP3, caspase-1  
4 (Casp-1), and ASC and their cytoplasmic co-localizations in bronchoalveolar lavage (BAL)  
5 cells. (A-C) Quantifications for the protein expressions of NLRP3 (A) and Casp-1 (B) and  
6 their cytoplasmic co-localization (C) in BAL cells from saline-exposed mice administered  
7 drug vehicle (SAL+VEH), *Af*-exposed mice administered drug vehicle (*Af*+VEH), *Af*-  
8 exposed mice administered 0.1 mg/kg IC87114 (*Af*+IC 0.1) or *Af*-exposed mice administered  
9 1.0 mg/kg IC87114 (*Af*+IC 1.0). (D-F) Quantifications for the protein expressions of ASC (D)  
10 and NLRP3 (E) and their cytoplasmic co-localization (F) in BAL cells from SAL+VEH,  
11 *Af*+VEH, *Af*+IC 0.1 or *Af*+IC 1.0. Bars represent mean  $\pm$  SEM from 6 mice per group. # $P <$   
12 0.05 versus SAL+VEH; \*  $P < 0.05$  versus *Af*+VEH.

13

14 **Supplementary Figure 5.** Effects of intratracheal administration of IC87114 on the cell  
15 viability. (A) Percentage of viable cell numbers in bronchoalveolar lavage (BAL) fluids from  
16 normal mice administered drug vehicle (CONT+VEH), normal mice administered 0.1 mg/kg  
17 IC87114 (CONT+IC 0.1), or normal mice administered 1.0 mg/kg IC87114 (CONT+IC 1.0).  
18 Bars represent mean  $\pm$  SEM from six mice per group. (B) Percentage of viable cell numbers  
19 in BAL fluids from *Aspergillus fumigatus* (*Af*)-exposed mice administered drug vehicle  
20 (*Af*+VEH), *Af*-exposed mice administered 0.1 mg/kg IC87114 (*Af*+IC 0.1), or *Af*-exposed  
21 mice administered 1.0 mg/kg IC87114 (*Af*+IC 1.0). Bars represent mean  $\pm$  SEM from six  
22 mice per group.

23

1 **Supplementary Figure 6.** Quantifications for the protein expressions of NLRP3, caspase-1  
2 (Casp-1), and ASC and their cytoplasmic co-localizations and mitochondrial reactive oxygen  
3 species (mtROS) in *Aspergillus fumigatus* (*Af*)-exposed experimental systems. (A-C)  
4 Quantifications of the immunofluorescence intensities for NLRP3 (A) and Casp-1 (B) and  
5 their cytoplasmic co-localization (C) in murine tracheal epithelial cells (EpCs) in the control  
6 (no treatment), *Af*-stimulated cells (*Af*), *Af*-stimulated cells administered drug vehicle  
7 (*Af*+VEH), or *Af*-stimulated cells administered IC87114 (*Af*+IC). (D-F) Quantifications of the  
8 immunofluorescence intensities for ASC (D) and NLRP3 (E) and their cytoplasmic co-  
9 localization (F) in murine tracheal EpCs in the control, *Af*, *Af*+VEH, or *Af*+IC. Bars represent  
10 mean  $\pm$  SEM from six independent experiments. <sup>#</sup>*P* < 0.05 versus control; \**P* < 0.05 versus  
11 cells stimulated with *Af* alone. (G-I) Quantifications of the immunofluorescence intensities  
12 for NLRP3 (G) and Casp-1 (H) and their cytoplasmic co-localization (I) in murine tracheal  
13 EpCs in the control (no treatment), *Af*-stimulated cells (*Af*), *Af*-stimulated cells administered  
14 scrambled siRNA (*Af*+Scram), or *Af*-stimulated cells administered PI3K- $\delta$  siRNA (*Af*+PI3K-  
15  $\delta$ ). Bars represent mean  $\pm$  SEM from six independent experiments. <sup>#</sup>*P* < 0.05 versus control;  
16 \**P* < 0.05 versus cells stimulated with *Af* transfected with scrambled siRNA. (J and K)  
17 Representative immunoblots and densitometric analyses of NLRP3 (J) and IL-1 $\beta$  (K) after  
18 stimulation with *Af* in EpCs in the presence or absence of IC87114. Bars represent mean  $\pm$   
19 SEM from six independent experiments. <sup>#</sup>*P* < 0.05 versus control; \**P* < 0.05 versus cells  
20 stimulated with *Af* alone. (L and M) Representative immunoblots and densitometric analyses  
21 of NLRP3 (L) and IL-1 $\beta$  (M) after stimulation with *Af* in EpCs transfected with either  
22 scrambled siRNA (Scram siRNA) or PI3K- $\delta$  siRNA. Bars represent mean  $\pm$  SEM from six  
23 independent experiments. <sup>#</sup>*P* < 0.05 versus control; \**P* < 0.05 versus cells transfected with  
24 Scram siRNA. (N) Quantifications of the fluorescence intensity for mtROS in  
25 bronchoalveolar lavage (BAL) cells from saline-exposed mice administered drug vehicle

1 (SAL+VEH), *Af*-exposed mice administered drug vehicle (*Af*+VEH), or *Af*-exposed mice  
2 administered NecroX-5 (*Af*+NX5). Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P*  
3 < 0.05 versus SAL+VEH; \**P* < 0.05 versus *Af*+VEH. (O) Quantifications of the fluorescence  
4 intensity for mtROS in BAL cells from saline-exposed mice administered drug vehicle  
5 (SAL+VEH), *Af*-exposed mice administered drug vehicle (*Af*+VEH), *Af*-exposed mice  
6 administered 0.1 mg/kg IC87114 (*Af*+IC 0.1), or *Af*-exposed mice administered 1.0 mg/kg  
7 IC87114 (*Af*+IC 1.0). Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05 versus  
8 SAL+VEH; \**P* < 0.05 versus *Af*+VEH. (P) Quantifications of the fluorescence intensity for  
9 mtROS in murine tracheal EpCs in the control, *Af*, *Af*+VEH, or *Af*+IC. Bars represent mean  $\pm$   
10 SEM from six independent experiments. <sup>#</sup>*P* < 0.05 versus control; \**P* < 0.05 versus cells  
11 stimulated with *Af* alone.

12

13 **Supplementary Figure 7.** Quantifications for the protein expressions of NLRP3, caspase-1  
14 (Casp-1), and ASC and their cytoplasmic co-localizations and mitochondrial reactive oxygen  
15 species (mtROS) in *Aspergillus fumigatus* (*Af*)-stimulated normal human bronchial epithelial  
16 (NHBE) cells. (A-C) Quantifications of the immunofluorescence intensities for NLRP3 (A)  
17 and Casp-1 (B) and their cytoplasmic co-localization (C) in the control (no treatment), *Af*-  
18 stimulated cells (*Af*), *Af*-stimulated cells administered drug vehicle (*Af*+VEH), or *Af*-  
19 stimulated cells administered IC87114 (*Af*+IC). (D-F) Quantifications of the  
20 immunofluorescence intensities for ASC (D) and NLRP3 (E) and their cytoplasmic co-  
21 localization (F) in the control, *Af*, *Af*+VEH, or *Af*+IC. Bars represent mean  $\pm$  SEM from six  
22 independent experiments. <sup>#</sup>*P* < 0.05 versus control; \**P* < 0.05 versus cells stimulated with *Af*  
23 alone. (G-I) Quantifications of the immunofluorescence intensities for NLRP3 (G) and Casp-  
24 1 (H) and their cytoplasmic co-localization (I) in the control (no treatment), *Af*-stimulated

1 cells (*Af*), *Af*-stimulated cells administered Non-targeting siRNA (*Af*+NT), or *Af*-stimulated  
2 cells administered PI3K- $\delta$  siRNA (*Af*+PI3K- $\delta$ ). Bars represent mean  $\pm$  SEM from six  
3 independent experiments. <sup>#</sup>*P* < 0.05 versus control; \**P* < 0.05 versus cells stimulated with *Af*  
4 transfected with Non-targeting siRNA. (J) Quantifications of the fluorescence intensity for  
5 mtROS in the control, *Af*, *Af*+VEH, or *Af*+IC. Bars represent mean  $\pm$  SEM from six  
6 independent experiments. <sup>#</sup>*P* < 0.05 versus control; \**P* < 0.05 versus cells stimulated with *Af*  
7 alone.

8

9 **Supplementary Figure 8.** Blockade of NLRP3 inflammasome improves *Alternaria alternata*  
10 (*Aa*)-induced allergic lung inflammation. (A) Cellular changes in bronchoalveolar lavage  
11 (BAL) fluids from saline-exposed mice administered drug vehicle (SAL+VEH), *Aa*-exposed  
12 mice administered drug vehicle (*Aa*+VEH), or *Aa*-exposed mice administered 50 mg/kg  
13 MCC 950 (*Aa*+MCC). Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05  
14 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH. (B-G) Representative H&E stained lung  
15 sections and their low power field view from SAL+VEH (B and E), *Aa*+VEH (C and F), and  
16 *Aa*+MCC (D and G), respectively. Bars indicate 50  $\mu$ m (200  $\mu$ m in low power field view). (H)  
17 Histopathologic quantifications of the inflammation scores of peri-bronchial, peri-vascular  
18 regions as well as total lung in SAL+VEH, *Aa*+VEH, or *Aa*+MCC. Bars represent mean  $\pm$   
19 SEM from six mice per group. <sup>#</sup>*P* < 0.05 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH. (I-M)  
20 Representative immunoblots and densitometric analyses of IL-4 (I), IL-5 (J), IL-13 (K), and  
21 IL-1 $\beta$  (L) in lung tissues and IL-1 $\beta$  in BAL fluids (M). Bars represent mean  $\pm$  SEM from six  
22 mice per group. <sup>#</sup>*P* < 0.05 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH.

23

1 **Supplementary Figure 9.** Blockade of phosphoinositide 3-kinase (PI3K)- $\delta$  improves  
2 *Alternaria alternata* (*Aa*)-induced allergic lung inflammation through regulation of NLRP3  
3 inflammasome. (A) Cellular changes in BAL fluids from saline-exposed mice administered  
4 drug vehicle (SAL+VEH), *Aa*-exposed mice administered drug vehicle (*Aa*+VEH), or *Aa*-  
5 exposed mice administered 0.1 mg/kg IC87114 (*Aa*+IC 0.1) or *Aa*-exposed mice  
6 administered 1.0 mg/kg IC87114 (*Aa*+IC 1.0). Bars represent mean  $\pm$  SEM from six mice per  
7 group. <sup>#</sup>*P* < 0.05 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH. (B-I) Representative H&E  
8 stained lung sections and their low power field view from SAL+VEH (B and F), *Aa*+VEH (C  
9 and G), *Aa*+IC 0.1 (D and H), and *Aa*+IC 1.0 (E and I), respectively. Bars indicate 50  $\mu$ m  
10 (200  $\mu$ m in low power field view). (J) Histopathologic quantifications of the inflammation  
11 scores of peri-bronchial, peri-vascular regions as well as total lung in SAL+VEH, *Aa*+VEH,  
12 *Aa*+IC 0.1, or *Aa*+IC 1.0. Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05  
13 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH. (K-O) Representative immunoblots and  
14 densitometric analyses of IL-4 (K), IL-5 (L), IL-13 (M), and IL-1 $\beta$  (N) in lung tissues and IL-  
15 1 $\beta$  in BAL fluids (O). Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05 versus  
16 SAL+VEH; \**P* < 0.05 versus *Aa*+VEH.

17

18 **Supplementary Figure 10.** Different responses to dexamethasone between two murine  
19 models of fungal allergic lung inflammation. (A) Airway responsiveness assessed by invasive  
20 measurements in saline-exposed mice administered drug vehicle (SAL+VEH), *Aspergillus*  
21 *fumigatus* (*Af*)-exposed mice administered drug vehicle (*Af*+VEH), and *Af*-exposed mice  
22 administered dexamethasone (*Af*+Dexa). Bars represent mean  $\pm$  SEM from six mice per  
23 group. <sup>#</sup>*P* < 0.05 versus SAL+VEH. (B) Cellular changes in bronchoalveolar lavage (BAL)  
24 fluids. Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05 versus SAL+VEH. To

1 = total cells; Mac = macrophages; Eo = eosinophils; Neut = Neutrophils; Lym =  
2 lymphocytes. (C-E) Representative H&E stained sections of the lung from SAL+VEH (C),  
3 *Af*+VEH (D), and *Af*+Dexa (E). Bars indicate 50  $\mu$ m. (F) Quantifications for histopathologic  
4 features through using threshold particle analysis in lung tissues from SAL+VEH, *Af*+VEH,  
5 or *Af*+Dexa. (G-I) Representative immunoblots and densitometric analyses of IL-4 (G), IL-5  
6 (H), and IL-13 (I) in lung tissues. Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* <  
7 0.05 versus SAL+VEH. (J) Airway responsiveness assessed by invasive measurements in  
8 saline-exposed mice administered drug vehicle (SAL+VEH), *Alternaria alternata* (*Aa*)-  
9 exposed mice administered drug vehicle (*Aa*+VEH), and *Aa*-exposed mice administered  
10 dexamethasone (*Aa*+Dexa). Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05  
11 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH. (K) Cellular changes in BAL fluids. Bars  
12 represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05 versus SAL+VEH; \**P* < 0.05  
13 versus *Aa*+VEH. (L-N) Representative H&E stained sections of the lung from SAL+VEH  
14 (L), *Aa*+VEH (M), and *Aa*+Dexa (N). Bars indicate 50  $\mu$ m. (O-Q) Representative  
15 immunoblots and densitometric analyses of IL-4 (O), IL-5 (P), and IL-13 (Q) in lung tissues.  
16 Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05 versus SAL+VEH; \**P* < 0.05  
17 versus *Aa*+VEH.

18

19 **Supplementary Figure 11.** Corticosteroid (CS)-resistant NLRP3 inflammasome contributes  
20 to *Aspergillus fumigatus* (*Af*)-induced allergic lung inflammation. (A and B) Representative  
21 immunoblots and densitometric analyses of IL-1 $\beta$  in lung tissues (A) and BAL fluids (B)  
22 from saline-exposed mice administered drug vehicle (SAL+VEH), *Aspergillus fumigatus*  
23 (*Af*)-exposed mice administered drug vehicle (*Af*+VEH), and *Af*-exposed mice administered  
24 dexamethasone (*Af*+Dexa). Bars represent mean  $\pm$  SEM from six mice per group. <sup>#</sup>*P* < 0.05

1 versus SAL+VEH. (C and D) Representative immunoblots and densitometric analyses of IL-  
2  $1\beta$  in lung tissues (C) and BAL fluids (D) from saline-exposed mice administered drug  
3 vehicle (SAL+VEH), *Alternaria alternata* (Aa)-exposed mice administered drug vehicle  
4 (Aa+VEH), and Aa-exposed mice administered dexamethasone (Aa+Dexa). Bars represent  
5 mean  $\pm$  SEM from six mice per group.  $^{\#}P < 0.05$  versus SAL+VEH;  $^{*}P < 0.05$  versus  
6 Aa+VEH. (E and F) Representative immunoblots and densitometric analysis of NLRP3 (E)  
7 and cleaved caspase-1 (F) in lung tissues from SAL+VEH, Af+VEH, or Af+Dexa. Bars  
8 represent mean  $\pm$  SEM from six mice per group.  $^{\#}P < 0.05$  versus SAL+VEH. (G and H)  
9 Representative immunoblots and densitometric analysis of NLRP3 (G) and cleaved caspase-1  
10 (H) in lung tissues from SAL+VEH, Aa+VEH, or Aa+Dexa. Bars represent mean  $\pm$  SEM  
11 from five mice per group.  $^{\#}P < 0.05$  versus SAL+VEH;  $^{*}P < 0.05$  versus Aa+VEH.

12

13 **Supplementary Figure 12.** Effects of dexamethasone on mitochondrial reactive oxygen  
14 species (mtROS) generation and nuclear translocation of nuclear factor (NF)- $\kappa$ B in lungs of  
15 two different murine models. (A) Representative confocal images show the localization of  
16 mtROS in bronchoalveolar lavage (BAL) cells from saline-exposed mice administered drug  
17 vehicle (SAL+VEH), *Aspergillus fumigatus* (Af)-exposed mice administered drug vehicle  
18 (Af+VEH), or Af-exposed mice administered dexamethasone (Af+Dexa) and their  
19 quantifications. Bars represent mean  $\pm$  SEM from six mice per group.  $^{\#}P < 0.05$  versus  
20 SAL+VEH. Bars indicate 20  $\mu$ m. (B) Representative confocal images show the localization  
21 of mtROS in BAL cells from saline-exposed mice administered drug vehicle (SAL+VEH),  
22 *Alternaria alternata* (Aa)-exposed mice administered drug vehicle (Aa+VEH), or Aa-exposed  
23 mice administered dexamethasone (Aa+Dexa) and their quantifications. Bars represent mean

1 ± SEM from six mice per group. <sup>#</sup>*P* < 0.05 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH.  
2 Bars indicate 20 μm. (C and D) Representative immunoblots and densitometric analyses of  
3 NF-κB p65 in nuclear (Nuc) (C) and cytosolic (Cyt) (D) extracts from lung tissues of  
4 SAL+VEH, *Af*+VEH, or *Af*+Dexa. Bars represent mean ± SEM from five mice per group. <sup>#</sup>*P*  
5 < 0.05 versus SAL+VEH. (E and F) Representative immunoblots and densitometric analyses  
6 of NF-κB p65 in nuclear (Nuc) (E) and cytosolic (Cyt) (F) extracts from lung tissues of  
7 SAL+VEH, *Aa*+VEH, or *Aa*+Dexa. Bars represent mean ± SEM from five mice per group.  
8 <sup>#</sup>*P* < 0.05 versus SAL+VEH; \**P* < 0.05 versus *Aa*+VEH.